Search research articles
Contact Us
Filters
Showing results (21-30 of 23) with videos related to
Page
of 3
Sort By:
You have reached the last page of results.
This site can display upto 23 results.
Cancer
|
November 15, 1995
Randomized phase III study of 5-fluorouracil plus high dose folinic acid versus 5-fluorouracil plus folinic acid plus methyl-lomustine for patients with advanced colorectal cancer
D V Jones, R J Winn, B W Brown, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 25, 2012
Risk factors for local and regional recurrence in patients with resected N0-N1 non-small-cell lung cancer, with implications for patient selection for adjuvant radiation therapy
J L Lopez Guerra, D R Gomez, S H Lin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 24, 2012
Addition of short-term androgen deprivation therapy to dose-escalated radiation therapy improves failure-free survival for select men with intermediate-risk prostate cancer
S X Bian, D A Kuban, L B Levy, et al.
Page
of 3
Search research articles
Search
Showing results (21-30 of 23) with videos related to
Sort By:
Page
of 3
You have reached the last page of results.
This site can display upto 23 results.
Cancer
|
November 15, 1995
Randomized phase III study of 5-fluorouracil plus high dose folinic acid versus 5-fluorouracil plus folinic acid plus methyl-lomustine for patients with advanced colorectal cancer
D V Jones, R J Winn, B W Brown, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 25, 2012
Risk factors for local and regional recurrence in patients with resected N0-N1 non-small-cell lung cancer, with implications for patient selection for adjuvant radiation therapy
J L Lopez Guerra, D R Gomez, S H Lin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 24, 2012
Addition of short-term androgen deprivation therapy to dose-escalated radiation therapy improves failure-free survival for select men with intermediate-risk prostate cancer
S X Bian, D A Kuban, L B Levy, et al.
Page
of 3